Post-operative chemoradiotherapy yields superior locoregional control, progression-free survival, and in some studies, overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies.
Downgrades, reversals, and omissions were most common among recommendations that were not supported by multiple randomized studies [ 24].
Multiple randomized studies have shown the benefit of thromboprophylaxis both in hospitalized patients with acute medical illness, including cancer, and in the surgical setting.
The Ann Arbor strain LAIV has been evaluated in multiple randomized controlled studies in children with a medical history of wheezing and asthma.
Systematic reviews of multiple randomized controlled studies have shown that PPI, misoprostol, and double-dose histamine-2-recpetor antagonist (H2RA) are effective at preventing chronic NSAID related endoscopic gastric and duodenal ulcers.
Multiple previous randomized studies and meta-analyses have evaluated the efficacy of such clinics with some suggesting a reduction in mortality in excess of 20% [ 1, 3, 6].
Over all, only 5 percent of the positive recommendations were supported by research from multiple double-blind randomized studies, the gold standard of evidence-based medicine.
Although our study provides a real-world look at practices and outcomes across multiple institutions, prospective randomized studies looking at C+G compared to G-CSF alone as well as plerixafor + G-CSF would further our knowledge and understanding of optimal and cost-effective methods of mobilization.
Their effectiveness in reducing fracture risk, including hip fracture (HF), safety, and good tolerability, has been demonstrated in multiple randomized, placebo-controlled clinical studies.
In the UK (time-series study, 5 to 8% effect size)[ 35]; Spain (time-series study, above 30% effect size)[ 111]; and Argentina (before-and-after study, 5 to 30% effect size),[ 69] This arrangement seems to have reinforced the P4P effect, although one cannot be sure due to the lack of randomized studies with multiple control groups.
Data from multiple randomized adjuvant trials and observational studies suggest that the rate of discontinuation of trastuzumab treatment ranges between 6 and 31%, mainly due to cardiotoxicity [2 10]; and in patients aged ≥65 years old, this figure increases to a notable and clinically relevant rate of 41%[11]].
